English | Russian | Kazakh
ONCOLOGY, NUCLEAR MEDICINE AND TRANSPLANTOLOGY
Review Article
Jul 13, 2026 10 6

Surgery in Metastatic Disease: When Is It Justified?

Peter Aduvie Josiah 1 * ,
Jennifer Adaobi Nkemdilim 2
1 Department of Medicine and Surgery, College of Health Sciences, Niger Delta University, Bayelsa State, Nigeria2 Institute for Health and Sport, Victoria University, Melbourne, Australia* Corresponding Author
Oncology, Nuclear Medicine and Transplantology, 2(3), 2026, onmt021, https://doi.org/10.63946/onmt/18956
Publication date: Jul 13, 2026
Full Text (PDF)

ABSTRACT

Surgery in metastatic cancer has been considered to have a limited role in the treatment of metastatic disease and has generally been reserved for palliative intent. However, as imaging, systemic therapy, surgical techniques, and understanding of the biology of cancer has improved, the role of surgery in the treatment of metastatic disease has evolved. This narrative review will discuss the current state of surgical therapy in metastatic cancer and the indications for such an approach. A discussion of the impact of reducing tumor burden, the concept of oligometastatic disease, and the role of host–tumor interactions will provide a basis for the discussion. The objectives of surgery have evolved from palliation to include longer survival and even potentially curative intent. The primary consideration in the decision to pursue surgical therapy for metastatic disease is proper patient selection, and this requires a thorough evaluation of disease and patient factors, as well as the integration of systemic therapy and other local therapies. While evidence is strongest for metastasectomy in colorectal cancer, there is growing evidence in breast cancer, renal cell carcinoma, lung cancer, and neuroendocrine tumors. As a general rule, the optimal management of metastatic cancer includes a combination of systemic and surgical therapies to maximize benefit for the patient. While there are limitations to the current role of surgical therapy in metastatic cancer, challenges including surgical morbidity, delays in initiation of necessary systemic therapy, and a paucity of high-quality evidence, proper patient selection remains the cornerstone to providing meaningful clinical benefit.

KEYWORDS

Metastatic Cancer Metastasectomy Oligometastatic Disease Tumor Burden Patient Selection

CITATION (Vancouver)

Josiah PA, Nkemdilim JA. Surgery in Metastatic Disease: When Is It Justified?. Oncology, Nuclear Medicine and Transplantology. 2026;2(3):onmt021. https://doi.org/10.63946/onmt/18956
APA
Josiah, P. A., & Nkemdilim, J. A. (2026). Surgery in Metastatic Disease: When Is It Justified?. Oncology, Nuclear Medicine and Transplantology, 2(3), onmt021. https://doi.org/10.63946/onmt/18956
Harvard
Josiah, P. A., and Nkemdilim, J. A. (2026). Surgery in Metastatic Disease: When Is It Justified?. Oncology, Nuclear Medicine and Transplantology, 2(3), onmt021. https://doi.org/10.63946/onmt/18956
AMA
Josiah PA, Nkemdilim JA. Surgery in Metastatic Disease: When Is It Justified?. Oncology, Nuclear Medicine and Transplantology. 2026;2(3), onmt021. https://doi.org/10.63946/onmt/18956
Chicago
Josiah, Peter Aduvie, and Jennifer Adaobi Nkemdilim. "Surgery in Metastatic Disease: When Is It Justified?". Oncology, Nuclear Medicine and Transplantology 2026 2 no. 3 (2026): onmt021. https://doi.org/10.63946/onmt/18956
MLA
Josiah, Peter Aduvie et al. "Surgery in Metastatic Disease: When Is It Justified?". Oncology, Nuclear Medicine and Transplantology, vol. 2, no. 3, 2026, onmt021. https://doi.org/10.63946/onmt/18956

REFERENCES

  1. Dillekås H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019 Aug;8(12):5574–6. doi: 10.1002/cam4.2474
  2. Korentzelos D, Clark AM, Wells A. A perspective on therapeutic pan-resistance in metastatic cancer. Int J Mol Sci. 2020 Oct 3;21(19):7304. doi: 10.3390/ijms21197304
  3. McCahill LE, Krouse R, Chu D, Juarez G, Uman GC, Ferrell B, et al. Indications and use of palliative surgery — results of Society of Surgical Oncology survey. Ann Surg Oncol. 2002 Jan–Feb;9(1):104–12. doi: 10.1245/aso.2002.9.1.104
  4. Abbas Z, Rehman S. An overview of cancer treatment modalities. In: Shahzad HN, editor. Neoplasm. London: IntechOpen; 2018. doi: 10.5772/intechopen.76558
  5. Pawlik TM. The Elusive Goal of Cancer Surgery: Patient and Provider Perception of "Cure". J Am Coll Surg. 2016;223(4 Suppl 2):e48. doi: 10.1016/j.jamcollsurg.2016.08.554
  6. Wang T, Ni Y, Liu L. Innovative imaging techniques for advancing cancer diagnosis and treatment. Cancers (Basel). 2024;16(14):2607. doi: 10.3390/cancers16142607
  7. Wyld L, Audisio R, Poston G. The evolution of cancer surgery and future perspectives. Nat Rev Clin Oncol. 2015;12:115–24. doi: 10.1038/nrclinonc.2014.191
  8. Patel S, Patkar S, Goel M. Extended indications of curative surgery in oligometastatic gallbladder cancers: survival benefit. HPB (Oxford). 2022;24(Suppl 1):S485–6. doi: 10.1016/j.hpb.2022.05.1043
  9. Debela DT, Kitaw TA, Daba DB, Tolesa FG, Negash BK, Fekadu SA, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021;9:20503121211034366. doi: 10.1177/20503121211034366
  10. Cliby WA. Advanced ovarian cancer: Weighing the risks and benefits of surgery. Clin Obstet Gynecol. 2020;63(1):74–9. doi: 10.1097/GRF.0000000000000497
  11. Ueno T. Surgical Management of Metastatic Breast Cancer: A Mini Review. Front Oncol. 2022;12:910544. doi: 10.3389/fonc.2022.910544
  12. Koti S, Demyan L, Deutsch G, Weiss M. Surgery for oligometastatic pancreatic cancer: defining biologic resectability. Ann Surg Oncol. 2024 Jun;31(6):4031–41. doi: 10.1245/s10434-024-15129-8
  13. Martorana E, Bruschi M, Scialpi P, Grisanti R, Scialpi M. Oligometastatic prostate cancer: is there a role for surgery? A narrative review. Turk J Urol. 2022 May 1;48(3):174–9. doi: 10.5152/tud.2022.22064
  14. Cheng B, Ye S, Bai P. The efficacy of cytoreductive surgery for oligometastatic prostate cancer: a meta-analysis. World J Surg Oncol. 2021 May 29;19(1):160. doi: 10.1186/s12957-021-02265-8
  15. Euhus CJ, Ripley TR, Medina CG. The role of surgery for oligometastatic non-small cell lung cancer. Cancers (Basel). 2022 May 20;14(10):2524. doi: 10.3390/cancers14102524
  16. Deek MP, Phillips R, Radwan N, Rowe SP, Antonarakis ES, Pienta KJ, et al. Oligometastatic and oligoprogression disease and local therapies in prostate cancer. Cancer J. 2020;26(2):137–43. doi: 10.1097/PPO.0000000000000432
  17. Kazi M, Pawar A, Saklani A, Bhatt A. Cytoreductive surgery for colorectal peritoneal metastasis in the era of modern systemic therapies: a systematic review and meta-analysis of survival outcomes. Int J Colorectal Dis. 2025;40:178. doi: 10.1007/s00384-025-04978-8
  18. Li X, Huang H, Ran L, Fang C, Yu Y, Luo M. Impact of ovarian metastatectomy on survival outcome of colorectal cancer patients with ovarian metastasis: a retrospective study. Cancer Manag Res. 2020;12:5671–80. doi: 10.2147/CMAR.S254876
  19. Rayson D, Bouttell E, Whiston F, Stitt L. Outcome after ovarian/adnexal metastectomy in metastatic colorectal carcinoma. J Surg Oncol. 2000;75(3):186–92. doi: 10.1002/1096-9098(200011)75:3<186::AID-JSO6>3.0.CO;2-S
  20. Yuan X, Liang H, Fu X, Yang S, Xiang C, Chen Z. Cytoreductive surgery with multimodal therapies in advanced or metastatic ovarian, colorectal, and gastric cancers: a systematic review and meta-analysis of randomized trials. World J Surg Oncol. 2025;23:286. doi: 10.1186/s12957-025-03908-w
  21. Climent MT, Serra A, Llueca A, Escrig J. Surgery in recurrent ovarian cancer: a meta-analysis. Cancers (Basel). 2023;15(13):3470. doi: 10.3390/cancers15133470
  22. Désolneux G, Mège D, Sabbagh C, Lakkis Z, Lelong B, Dazza M, et al. Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLoS One. 2015;10(3):e0122816. doi: 10.1371/journal.pone.0122816
  23. Mintzer D. The changing role of surgery in the diagnosis and treatment of cancer. Am J Med. 1999;106(1):81–9. doi: 10.1016/S0002-9343(98)00373-8
  24. Dreyer SB, Pinese M, Jamieson NB, Scarlett CJ, Colvin EK, Pajic M, et al. Precision oncology in surgery: patient selection for operable pancreatic cancer. Ann Surg. 2020 Aug;272(2):366–76. doi: 10.1097/SLA.0000000000003143
  25. Treasure T, Milošević M, Fiorentino F, Macbeth F. Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? Thorax. 2014;69(10):946–9. doi: 10.1136/thoraxjnl-2013-204528
  26. Petrella F, Diotti C, Rimessi A, Spaggiari L. Pulmonary metastasectomy: an overview. J Thorac Dis. 2017;9(Suppl 12):S1291–S1298. doi: 10.21037/jtd.2017.03.175
  27. Apollonio G, Raimondi A, Verzoni E, Claps M, Sepe P, Procopio G. The role of metastasectomy in advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2019;19(7):603–11. doi: 10.1080/14737140.2019.1625772
  28. Lee RM, Ethun CG, Gamboa AC, Turgeon MK, Tran T, Poultsides G, et al. A novel preoperative risk score to guide patient selection for resection of soft tissue sarcoma lung metastases: An analysis from the United States Sarcoma Collaborative. J Surg Oncol. 2021;124(8):1283–92. doi: 10.1002/jso.26635
  29. Delisle M, Alshamsan B, Nagaratnam K, Smith D, Wei Y. Metastasectomy in leiomyosarcoma: a systematic review and pooled survival analysis. Cancers (Basel). 2022;14(13):3055. doi: 10.3390/cancers14133055
  30. Rosenman J, Varia M. Prognostic significance of disease-free interval. In: Stoll BA, editor. Pointers to Cancer Prognosis. Developments in Oncology, vol 48. Dordrecht: Springer; 1987. doi: 10.1007/978-94-009-3291-3_4
  31. Erhunmwunsee L, Tong BC. Preoperative evaluation and indications for pulmonary metastasectomy. Thorac Surg Clin. 2016;26(1):7–12. doi: 10.1016/j.thorsurg.2015.09.002
  32. West H, Jin JO. Performance status in patients with cancer. JAMA Oncol. 2015;1(7):998. doi: 10.1001/jamaoncol.2015.3113
  33. Silbermann M, Pitsillides B, Al-Omari A, Al-Kurdi M, El-Shamy M, Ghrayeb I, et al. Multidisciplinary care team for cancer patients and its implementation in several Middle Eastern countries. Ann Oncol. 2013;24(Suppl 7):vii41–7. doi: 10.1093/annonc/mdt265
  34. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–57; discussion 657–8. doi: 10.1097/01.sla.0000141198.92114.f6
  35. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–80. doi: 10.1200/JCO.2007.11.0833
  36. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16. doi: 10.1016/S0140-6736(08)60455-9
  37. Williams NR, Patrick H, Fiorentino F, Allen A, Sharma M. Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) randomized controlled trial: a systematic review of published responses. Eur J Cardiothorac Surg. 2022;62(1):ezac253. doi: 10.1093/ejcts/ezac253
  38. Badwe RA, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16(13):1380–8. doi: 10.1016/S1470-2045(15)00135-7
  39. Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: Protocol MF07-01. Ann Surg Oncol. 2018;25(11):3141–9. doi: 10.1245/s10434-018-6494-6
  40. Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417–27. doi: 10.1056/NEJMoa1803675
  41. Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol. 2019;5(2):164–70. doi: 10.1001/jamaoncol.2018.5543
  42. Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–82. doi: 10.1016/S1470-2045(16)30532-0
  43. Delle Fave G, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology. 2016;103(2):119–24. doi: 10.1159/000443168
  44. Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012 Aug;19(8):2547–55. doi: 10.1245/s10434-012-2398-z
  45. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53. doi: 10.1056/NEJMoa0908806
  46. Badgwell B. Palliative surgery. J Cancer Policy. 2016;10:36–9. doi: 10.1016/j.jcpo.2016.05.001
  47. Boyes DA, Rebbeck PM, Dawson AE. Embolisation of cancer: what is the evidence? Cancer Imaging. 2004 Sep 17;4(2):133–41. doi: 10.1102/1470-7330.2004.0021
  48. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria — a 10-year update. J Vasc Interv Radiol. 2014 Nov;25(11):1691–705.e4. doi: 10.1016/j.jvir.2014.08.027
  49. Chan G, Chee CE. Perioperative chemotherapy for liver metastasis of colorectal cancer. Cancers (Basel). 2020 Nov 26;12(12):3535. doi: 10.3390/cancers12123535
  50. Zhang H, Huang Z, Zou X, Liu T. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2016 Dec 13;7(50):82473–81. doi: 10.18632/oncotarget.12666
  51. Tan S, Li D, Zhu X. Cancer immunotherapy: pros, cons and beyond. Biomed Pharmacother. 2020 Apr;124:109821. doi: 10.1016/j.biopha.2020.109821
  52. Friedman M, Mikityansky I, Kam A, Libutti SK, Walther MM, Neeman Z, et al. Radiofrequency ablation of cancer. Cardiovasc Intervent Radiol. 2004 Sep–Oct;27(5):427–34. doi: 10.1007/s00270-004-0062-0
  53. Pearce J, Martin S, Heritage S, Khoury EG, Kucharczak J. Frailty and outcomes in adults undergoing systemic anticancer treatment: a systematic review and meta-analysis. JNCI J Natl Cancer Inst. 2025;117(7):1316–39. doi: 10.1093/jnci/djaf017
  54. Boakye D, Rillmann B, Walter V, Jansen L, Hoffmeister M, Brenner H. Impact of comorbidity and frailty on prognosis in colorectal cancer patients: A systematic review and meta-analysis. Cancer Treat Rev. 2018;64:30–9. doi: 10.1016/j.ctrv.2018.02.003
  55. Martos-Benítez FD, Gutiérrez-Noyola A, Echevarría-Víctores A. Postoperative complications and clinical outcomes among patients undergoing thoracic and gastrointestinal cancer surgery: A prospective cohort study. Rev Bras Ter Intensiva. 2016;28(4):211–7. doi: 10.5935/0103-507X.20160012
  56. Wassie LA, Tsega SS, Melaku MS, Aemro A. Delayed treatment initiation and its associated factors among cancer patients at Northwest Amhara referral hospital oncology units: A cross-sectional study. Int J Africa Nurs Sci. 2023;18:100568. doi: 10.1016/j.ijans.2023.100568
  57. Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087. doi: 10.1136/bmj.m4087
  58. Treasure T, Macbeth F. The belief in clinical benefit from lung metastasectomy in colorectal cancer is questioned by the PulMiCC study and its nested randomised controlled trial. Langenbecks Arch Surg. 2024;409:262. doi: 10.1007/s00423-024-03457-y
  59. Treasure T, Macbeth F, Farewell V, Williams NR, Fallowfield L. The fallacy of large survival gains from lung metastasectomy in colorectal cancer. Lancet. 2021;397(10269):97–8. doi: 10.1016/S0140-6736(20)32760-4
  60. Cook JA. The challenges faced in the design, conduct and analysis of surgical randomised controlled trials. Trials. 2009;10:9. doi: 10.1186/1745-6215-10-9
  61. Cherny NI, Nortjé N, Kelly R, Zimmermann C, Jordan K, Kreye G, et al. A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed? ESMO Open. 2025;10(1):104099. doi: 10.1016/j.esmoop.2024.104099
  62. Vakili-Ojarood M, Rahmani A. Ethical considerations and equipoise in cancer surgery. Indian J Surg Oncol. 2024;15(Suppl 2):S1–S8. doi: 10.1007/s13193-024-02023-8
  63. Adi-Wauran E, Krishnapillai S, Uleryk E, Saeedi S, Bombard Y. Patient-centred care in precision oncology: a systematic review. Patient Educ Couns. 2025;136:108753. doi: 10.1016/j.pec.2025.108753
  64. Boddy A. Enhancing informed consent in oncological surgery through digital platforms and artificial intelligence. Clin Surg Oncol. 2025;4(2):100080. doi: 10.1016/j.cson.2025.100080
  65. Mansour R, Abdel-Razeq H, Al-Hussaini M, Shamieh O, Al-Ibraheem A, Al-Omari A, et al. Systemic barriers to optimal cancer care in resource-limited countries: Jordanian healthcare as an example. Cancers (Basel). 2024;16(6):1117. doi: 10.3390/cancers16061117
  66. Chung H, Crone E, Gough K, Hyatt A, Milne D, Krishnasamy M. Equity in cancer care: mixed methods clinical utility analysis of the Nursing Equity Assessment Tool (NEAT) to identify disadvantage in newly diagnosed cancer patients. Support Care Cancer. 2025;33(1):60. doi: 10.1007/s00520-024-09094-x
  67. Specchia ML, Frisicale EM, Carini E, Di Pilla A, Cappa D, Barbara A, et al. The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res. 2020 Jan 31;20(1):73. doi: 10.1186/s12913-020-4930-3
  68. Elder K. The role of the surgeon in cancer care. Surgery (Oxford). 2024;42(3):129–34. doi: 10.1016/j.mpsur.2023.12.006
  69. Edge SB. The role of the surgeon in quality cancer care. Curr Probl Surg. 2003;40(9):511–90. doi: 10.1016/S0011-3840(03)00051-0
  70. Yıldırım ÖA, Erdur E. Medical oncology or surgical oncology: which branch should be started in esophageal cancer diagnostic evaluation? Cureus. 2022;14(2):e22286. doi: 10.7759/cureus.22286
  71. Valentini V, Boldrini L, Mariani S, Massaccesi M. Role of radiation oncology in modern multidisciplinary cancer treatment. Mol Oncol. 2020;14(7):1431–41. doi: 10.1002/1878-0261.12712
  72. Godrie F, van Zuilekom I, Onwuteaka-Philipsen B, van Os-Medendorp H. Specialized expertise among healthcare professionals in palliative care - A scoping review. BMC Palliat Care. 2024;23:177. doi: 10.1186/s12904-024-01498-0
  73. Kleeff J, Rebelo A. Surgical oncology in 2025: challenges, innovations, and the road ahead for young surgical oncologists. Curr Oncol. 2025;32(9):478. doi: 10.3390/curroncol32090478
  74. Yagin FH, Yagin B, Colak C, Alkhateeb A, Rueda L, Dehzangi A, et al. Cancer metastasis prediction and genomic biomarker identification through machine learning and eXplainable artificial intelligence in breast cancer research. Diagnostics (Basel). 2023;13(21):3314. doi: 10.3390/diagnostics13213314
  75. Klement GL, Arkun K, Valik D, Roffidal T, Hashemi A, Klement C, et al. Future paradigms for precision oncology. Oncotarget. 2016;7(29):46813–31. doi: 10.18632/oncotarget.9488
  76. Zang Y, Lee JJ. Adaptive clinical trial designs in oncology. Chin Clin Oncol. 2014;3(4):49. doi: 10.3978/j.issn.2304-3865.2014.06.04
  77. Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016 Jul 6;8(346):346ra92. doi: 10.1126/scitranslmed.aaf6219
  78. Reinert T, Schøler LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2016 Apr;65(4):625–34. doi: 10.1136/gutjnl-2014-308859
  79. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26;386(21):1973–85. doi: 10.1056/NEJMoa2202170
  80. Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020 Nov;21(11):1413–22. doi: 10.1016/S1470-2045(20)30453-8
  81. Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, et al. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018;9(1):1793. doi: 10.1038/s41467-018-04278-6

LICENSE

Creative Commons License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.